The effectiveness of anti-PD-L1 treatment and the underlying regulatory mechanism in ovarian clear cell carcinoma
Ovarian clear cell carcinoma (OCCC) is typically associated with a poor prognosis. However, recent clinical trials have demonstrated that OCCC exhibits a nice response rate to immunotherapy. To identify whether anti-PD-L1 treatment was effective in OCCC and explore the underlying mechanism of the effectiveness. Western blot, real-time PCR, RNA Pull down protein mass spectrometry studies, and RIP experiments were accordingly used to detect ZFPM2-AS1/ HNRNPC/ PD-L1 axis at the level of molecular, cellular and animal experimental model, respectively. Flow cytometry analysis, the wound healing and transwell assay were conducted to detect the OCCC biological behaviors. In our study, we clearly identified the effectiveness of anti-PD-L1 treatment in OCCC, and found PD-L1 was highly expressed in OCCC and was closely related to the proliferation, invasion and metastasis in vitro and in vivo. In addition, ZFPM2-AS1 was also find overexpression in OCCC and could combine to HNRNPC, and ZFPM2-AS1/HNRNPC axis participated in regulating the effectiveness of anti-PD-L1 treatment. Our study provided a therapeutic regime that is urgently needed in OCCC and full of prospects.
Authors
- Jun Zhu (ORCID: https://orcid.org/0000-0003-1224-2771)
- Guihao Ke (ORCID: https://orcid.org/0000-0002-1253-5083)
- Yong Wu (ORCID: https://orcid.org/0000-0003-3764-3846)
- Meiqun Jia
- Qinhao Guo (ORCID: https://orcid.org/0000-0003-4661-481X)
- Ying Wu (ORCID: https://orcid.org/0000-0001-5218-2983)
- Jiangchun Wu
- Chi Fang
Institutions
- Second Military Medical University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Shanghai Changzheng Hospital (CN)
- Nantong Tumor Hospital (CN)
Publication Details
- Journal
- International Immunopharmacology
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1016/j.intimp.2025.115344
- Citations
- 1
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.70